Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 3,618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intestinal Cancer Clear all
Completed Phase 1 Interventional Results available

Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission

NCT02365480
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Berberine Chloride, Laboratory Biomarker Analysis, Placebo Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 24, 2026, 1:42 AM EDT
Withdrawn Phase 2 Interventional

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

NCT05178576
View directory record Official record
Conditions
Colon Cancer
Interventions
Gevokizumab, Signatera test
Drug · Diagnostic Test
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Gainesville, Florida • Iowa City, Iowa • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 24, 2026, 1:42 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Choose It and Use It: Choice, Implementation Intentions and At-Home Colorectal Cancer Screening

NCT06085560
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Usual Care Message, Implementation Intention Intervention: Standard Message, Implementation Intention Intervention: Culturally-Targeted Message
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
45 Years to 72 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 24, 2026, 1:42 AM EDT
Not listed No phase listed Observational

An Investigation of Small Intestinal Carcinoid Carcinoma in Families

NCT00662168
View directory record Official record
Conditions
Carcinoid Carcinoma
Interventions
Not listed
Lead sponsor
Rutgers University
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Oct 24, 2026, 1:42 AM EDT
Terminated Phase 2 Interventional Results available

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

NCT03785210
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, Liver Metastasis
Interventions
nivolumab, tadalafil, oral vancomycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 24, 2026, 1:42 AM EDT
Terminated Phase 1 Interventional

Eniluracil Hand Foot Syndrome

NCT00827580
View directory record Official record
Conditions
Breast Cancer, Colon Cancer
Interventions
Eniluracil
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 24, 2026, 1:42 AM EDT
Completed Phase 2 Interventional Results available

Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer

NCT02138617
View directory record Official record
Conditions
Colon Cancer
Interventions
5-Fluorouracil, Leucovorin, Irinotecan, Bevacizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 24, 2026, 1:42 AM EDT
Terminated Phase 1Phase 2 Interventional

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

NCT00147550
View directory record Official record
Conditions
Melanoma, Colonic Neoplasms, Breast Neoplasms
Interventions
PD-0325901
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • La Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 24, 2026, 1:42 AM EDT
Terminated Not applicable Interventional Results available

Blue and Amber Light Exposure in Patients With Rectal and Pancreatic Cancer

NCT06164691
View directory record Official record
Conditions
Pancreatic Neoplasms, Rectal Neoplasms
Interventions
Blue light, Amber light, Ambient White Light
Device · Other
Lead sponsor
Matthew Neal MD
Other
Eligibility
19 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 24, 2026, 1:42 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver

NCT00001576
View directory record Official record
Conditions
Colorectal Neoplasm, Liver Neoplasm, Neoplasm Metastasis
Interventions
Melphalan, Floxuridine, Leucovorin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 1:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Text-based Colorectal Cancer Prevention Pilot

NCT05004376
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Text Messaging
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
45 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 24, 2026, 1:42 AM EDT
Terminated No phase listed Observational

Do Patients With Colorectal Cancer Understand That Their Family is at Risk?

NCT00145860
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 24, 2026, 1:42 AM EDT
Completed Phase 2 Interventional Results available

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

NCT04166435
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Temozolomide + Olaparib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 24, 2026, 1:42 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Healthcare Decisions Post-Testing, Risk-reducing and Preventative Strategies Using LYNCH Genetic Testing Reducing, and Preventative Strategies Using LYNCH Genetic Testing

NCT03322176
View directory record Official record
Conditions
Colon Cancer, Endometrial Cancer
Interventions
Genetic testing
Other
Lead sponsor
Data Collection Analysis Business Management
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Land O' Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 24, 2026, 1:42 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer

NCT00019110
View directory record Official record
Conditions
Anal Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Penile Cancer, Vulvar Cancer
Interventions
human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
6
States / cities
Bethesda, Maryland • Boston, Massachusetts • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 24, 2026, 1:42 AM EDT
Terminated No phase listed Observational

QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT

NCT00568425
View directory record Official record
Conditions
Anal Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 24, 2026, 1:42 AM EDT
Completed Phase 1 Interventional Results available

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention

NCT03817125
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Placebo for antibiotic, Vancomycin pretreatment, Nivolumab, Matching Placebo for SER-401, SER-401
Drug
Lead sponsor
Parker Institute for Cancer Immunotherapy
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 24, 2026, 1:42 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

NCT04017650
View directory record Official record
Conditions
BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Progressive Disease, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Cetuximab, Encorafenib, Nivolumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 24, 2026, 1:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

NCT01750918
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib, Panitumumab, 5-fluorouracil
Drug · Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 24, 2026, 1:42 AM EDT
Recruiting Not applicable Interventional

Colorectal Cancer Screening Outreach

NCT07345676
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
Bundled messaging intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
45 Years to 75 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 24, 2026, 1:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, Metastatic Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Acinar Cell Carcinoma
Interventions
ART0380, Gemcitabine, Irinotecan
Drug
Lead sponsor
Artios Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 1:42 AM EDT
Completed No phase listed Observational

Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy

NCT00414232
View directory record Official record
Conditions
Rectal Cancer
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 24, 2026, 1:42 AM EDT
Completed No phase listed Observational

PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

NCT05697198
View directory record Official record
Conditions
Lung Cancer, Ovarian Cancer, Uterine Cancer, Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Melanoma, Breast Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Rhabdomyosarcoma, Prostate Cancer
Interventions
OmniSeq Test
Diagnostic Test
Lead sponsor
Labcorp Corporation of America Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Fort Payne, Alabama • Orange City, Florida • Stuart, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 24, 2026, 1:42 AM EDT
Recruiting Phase 2 Interventional

Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)

NCT07795749
View directory record Official record
Conditions
Esophageal Carcinoma, Gastric Cancer (Diagnosis), Colorectal Adenocarcinoma, Appendiceal Adenocarcinoma, Small Bowel Adenocarcinoma, Hepatobiliary Carcinoma in Situ
Interventions
Paclitaxel Q2W, Paclitaxcel Q3W
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 24, 2026, 1:42 AM EDT